Saghmos Receives Second US Patent for Phase 3 Cardiorenal Drug ST-62516

Saghmos Therapeutics, a biopharmaceutical firm, has received a second US patent for its Phase 3 candidate, ST-62516, which is a cardiorenal metabolic modulator. The patent, which will be exclusive until 2037, covers the prevention of acute kidney injury (AKI) and major adverse cardiac and kidney events (MACKE) in patients with chronic kidney disease (CKD) who undergo contrast procedures.

The company's CEO, Anna Kazanchyan, expressed satisfaction with the patent, which she believes will increase the value of ST-62516 and strengthen Saghmos' intellectual property portfolio. ST-62516 is being developed to mitigate the risk of AKI and MACKE following contrast procedures such as percutaneous coronary intervention (PCI). The FDA approved Saghmos' IND for ST-62516 in July 2023, and the drug is set to be administered to patients for 90 days, beginning just before the PCI procedure.

In the US, over one million PCI procedures are conducted annually, often in patients with unstable angina. Many of these patients have other health issues such as heart disease, diabetes, or are over 75 years old, which can affect the safety of PCI. Procedure-related factors can also lead to AKI and MACKE, creating a significant medical need that currently has no FDA-approved drugs for prevention or treatment. ST-62516 has the potential to benefit all PCI patients, including those without other health issues, by reducing the risk of AKI and MACKE post-PCI.

Saghmos Therapeutics has already been granted a US patent (number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures. The company recently appointed Fred Hassan as Chairman of the Board of Directors.